May 2012

Semuloparin significantly decreases the risk of thromboembolic events in cancer patients initiating chemotherapy compared with placebo, and without a hike in major bleeding.

The U-M Comprehensive Cancer Center in Ann Arbor offers diagnostic, treatment, and support services while serving as a model for other branches of the U-M Health System and for academic peer organizations nationwide.

An interview with ASCO President Michael P. Link, MD, discussing the impact of oncology drug shortages.

To date, no studies of novel therapies combined with docetaxel and prednisone have demonstrated improvement in their designated endpoints. However, several promising combination trials are ongoing.

Focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Liver surgery for colorectal cancer hepatic metastases has, for the most part, a minimal and brief negative impact on patient-reported outcomes.

Oliver Sartor, MD, and Leonard G. Gomella, MD, discuss multiple topics involved with prostate-specific antigen (PSA) screening, including PSA velocity, guidelines, and cutoff age.

Breast cancer survivors who are younger, closer to the time of surgery, or have upper-extremity lymphedema may be less likely to undergo repeat mammography.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Leonard G. Gomella, MD, discusses the public policy and medical implications of the US Preventive Services Task Force's draft recommendation on PSA screening.

Within a given county in the United States, the presence of a dermatologist is associated with a lower melanoma mortality rate compared with counties where there is no dermatologist.

Patients are less likely to complete colorectal cancer screening if their physician recommended colonoscopy rather than recommending fecal occult blood testing.

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Lately, business and government have done more to "move the needle" in changing healthcare delivery than physicians, scientists, and other clinical professionals.